Vertex Pharmaceuticals Incorporated vs Jazz Pharmaceuticals plc: SG&A Expense Trends

SG&A Expense Trends: Vertex vs. Jazz Pharmaceuticals

__timestampJazz Pharmaceuticals plcVertex Pharmaceuticals Incorporated
Wednesday, January 1, 2014406114000305409000
Thursday, January 1, 2015449119000377080000
Friday, January 1, 2016502892000432829000
Sunday, January 1, 2017544156000496079000
Monday, January 1, 2018683530000557616000
Tuesday, January 1, 2019736942000658498000
Wednesday, January 1, 2020854233000770456000
Friday, January 1, 20211451683000840100000
Saturday, January 1, 20221416967000944700000
Sunday, January 1, 202313431050001136600000
Monday, January 1, 20241464300000
Loading chart...

Unleashing the power of data

SG&A Expense Trends: Vertex vs. Jazz Pharmaceuticals

In the competitive landscape of pharmaceuticals, understanding financial trends is crucial. Over the past decade, from 2014 to 2023, Vertex Pharmaceuticals Incorporated and Jazz Pharmaceuticals plc have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. Jazz Pharmaceuticals has consistently outpaced Vertex, with its SG&A expenses peaking at approximately 1.45 billion in 2021, marking a 258% increase from 2014. Meanwhile, Vertex's expenses grew by 272% over the same period, reaching around 1.14 billion in 2023. This growth reflects strategic investments in marketing and administration, crucial for maintaining competitive advantage. Notably, both companies experienced significant expense surges in 2021, likely due to increased operational activities. These trends highlight the dynamic nature of the pharmaceutical industry, where financial agility can be as critical as scientific innovation.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025